Skip to main content
SpringerLink
Log in

Anti-Müller-Hormon (AMH)

Anti-Mullerian hormone (AMH)

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Anti-Müller-Hormon (AMH) wird beim Mann von den Sertoli-Zellen und bei der Frau von den Granulosazellen produziert. Interessant ist es klinisch v. a. während der reproduktiven Phase der Frau zur Beurteilung der ovariellen Reserve. Hauptsächlich sezernieren Primärfollikel, Sekundärfollikel und frühe antrale Follikel das AMH. Somit reflektiert der Serumspiegel von AMH in verlässlicher Weise den Follikelpool. AMH korreliert insofern sehr gut mit dem Alter, ferner mit der Eizellzahl im Rahmen der IVF (In-vitro-Fertilisation), der Schwangerschaftsrate und der Geburtenrate. AMH ist relativ zyklusunabhängig, zeigt aber einen (geringen) Abfall postovulatorisch. Unter oralen Kontrazeptiva und in der Schwangerschaft ist AMH unverändert nachweisbar, sodass man auch in diesen Situationen die ovarielle Reserve beurteilen kann. Darüber hinaus kann AMH als Tumormarker für Granulosazelltumoren dienen. Bei Neugeborenen oder Kindern mit unklarer Geschlechtszuordnung ist AMH hilfreich, da es bei Vorhandensein von Hoden deutlich erhöht ist.

Abstract

Anti-Mullerian hormone (AMH) is produced by Sertoli cells in men and granulosa cells in women. It is interesting from a clinical point of view in evaluating the ovarian reserve in women of reproductive age. AMH is mainly produced by primary, secondary and early antral follicles and is therefore a marker of the growing follicle pool in the ovary. AMH correlates with age, with the number of oocytes retrieved in an in vitro fertilization (IVF) cycle and with the pregnancy and birth rate. AMH is stable over the cycle, with only a small drop after ovulation. AMH is stable and can be measured to evaluate the ovarian reserve during treatment with oral contraceptive pills and during pregnancy. AMH is also a useful tumor marker for granulosa cell tumors. In newborns or children with intersex disorders, AMH can be measured to evaluate whether or not testicular tissue is present.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Andersen CY, Byskov AG (2006) Estradiol and regulation of anti-Mullerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles‘ fluid. J Clin Endocrinol Metab 91: 4064–4069

    Article  PubMed  CAS  Google Scholar 

  2. Anderson RA, Themmen AP, Al-Qahtani A et al. (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21: 2583–2592

    Article  PubMed  CAS  Google Scholar 

  3. de Vet A, Laven JS, de Jong FH et al. (2002) Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77: 357–362

    Article  Google Scholar 

  4. Elgindy EA, El-Haieg DO, El-Sebaey A (2007) Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril (in press)

  5. Fanchin R, Schonauer LM, Righini C et al. (2003) Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18: 323–327

    Article  PubMed  CAS  Google Scholar 

  6. Feyereisen E, Mendez Lozano DH, Taieb J et al. (2006) Anti-Mullerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online 12: 695–703

    PubMed  CAS  Google Scholar 

  7. Fleming R, Deshpande N, Traynor I, Yates RW (2006) Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 21: 1436–1441

    Article  PubMed  CAS  Google Scholar 

  8. Fraisse T, Ibecheole V, Streuli I et al. (2007) Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril (in press)

  9. Freeman EW, Gracia CR, Sammel MD et al. (2007) Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 87: 101–106

    Article  PubMed  CAS  Google Scholar 

  10. Freour T, Mirallie S, Bach-Ngohou K et al. (2007). Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375: 162–164

    Article  PubMed  CAS  Google Scholar 

  11. Gustafson ML, Lee MM, Scully RE et al. (1992) Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 326: 466–471

    PubMed  CAS  Google Scholar 

  12. Hazout A, Bouchard P, Seifer DB et al. (2004) Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82: 1323–1329

    Article  PubMed  CAS  Google Scholar 

  13. Kevenaar ME, Themmen AP, Rivadeneira F et al. (2007) A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 22: 2382–2388

    Article  PubMed  CAS  Google Scholar 

  14. La Marca A, Giulini S, Orvieto R et al. (2005) Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 20: 1569–1572

    Article  Google Scholar 

  15. La Marca A, Malmusi S, Giulini S et al. (2004) Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19: 2738–2741

    Article  CAS  Google Scholar 

  16. La Marca A, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21: 3103–3107

    Article  Google Scholar 

  17. La Marca A, Volpe A (2007) The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update 13: 265–273

    Article  Google Scholar 

  18. Lane AH, Lee MM, Fuller AF et al. (1999) Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 73: 51–55

    Article  PubMed  CAS  Google Scholar 

  19. Laven JS, Mulders AG, Visser JA et al. (2004) Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89: 318–323

    Article  PubMed  CAS  Google Scholar 

  20. Lee MM, Donahoe PK (1993) Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 14: 152–164

    Article  PubMed  CAS  Google Scholar 

  21. Long WQ, Ranchin V, Pautier P et al. (2000) Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 85: 540–544

    Article  PubMed  CAS  Google Scholar 

  22. Nakhuda GS, Sauer MV, Wang JG et al. (2007) Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reprod Biomed Online 14: 450–454

    Article  PubMed  CAS  Google Scholar 

  23. Nelson SM, Yates RW, Fleming R (2007) Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Hum Reprod 22: 2414–2421

    Article  PubMed  CAS  Google Scholar 

  24. Pigny P, Jonard S, Robert Y, Dewailly D (2006) Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91: 941–945

    Article  PubMed  CAS  Google Scholar 

  25. Rey RA, Lhomme C, Marcillac I et al. (1996) Antimullerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 174: 958–965

    Article  PubMed  CAS  Google Scholar 

  26. Seifer DB, MacLaughlin DT, Christian BP et al. (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77: 468–471

    Article  PubMed  Google Scholar 

  27. Somunkiran A, Yavuz T, Yucel O, Ozdemir I (2007) Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 134: 196–201

    Article  PubMed  CAS  Google Scholar 

  28. Streuli I, Fraisse T, Pillet C et al. (2007) Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril (in press)

  29. Teixeira J, Maheswaran S, Donahoe PK (2001) Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22: 657–674

    Article  PubMed  CAS  Google Scholar 

  30. Thum MY, Abdalla HI, Taylor D (2007) Relationship between women’s age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment. Fertil Steril (in press)

  31. Tsepelidis S, Devreker F, Demeestere I et al. (2007) Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 22: 1837–1840

    Article  PubMed  CAS  Google Scholar 

  32. van Beek RD, van den Heuvel-Eibrink MM, Laven JS et al. (2007) Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab 92: 3869–3874

    Article  CAS  Google Scholar 

  33. van der Steeg JW, Steures P, Eijkemans MJ et al. (2007) Predictive value and clinical impact of Basal follicle-stimulating hormone in subfertile, ovulatory women. J Clin Endocrinol Metab 92: 2163–2168

    Article  CAS  Google Scholar 

  34. van Rooij I, Broekmans FJ, Scheffer GJ et al. (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83: 979–987

    Article  CAS  Google Scholar 

  35. van Rooij I, Broekmans FJ, Te Velde ER et al. (2002) Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17: 3065–3071

    Article  Google Scholar 

  36. Wachs DS, Coffler MS, Malcom PJ, Chang RJ (2007) Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 92: 1871–1874

    Article  PubMed  CAS  Google Scholar 

  37. Wunder DM, Bersinger NA, Yared M et al. (2007) Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril (in press)

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und Pränatale Medizin, ENDOKRINOLOGIKUM Hamburg, Lornsenstraße 4–6, 22767, Hamburg, Deutschland

    M. Ludwig

Authors
  1. M. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Ludwig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludwig, M. Anti-Müller-Hormon (AMH). Gynäkologische Endokrinologie 6, 115–122 (2008). https://doi.org/10.1007/s10304-008-0234-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-008-0234-0

Schlüsselwörter

Keywords

Search

Navigation